Blackstone Life Sciences, Johnson & Johnson Fund Bleximenib
Analysis based on 7 articles · First reported Feb 23, 2026 · Last updated Feb 23, 2026
The market is likely to view this co-funding agreement positively, as it accelerates the development of a promising treatment for acute myeloid leukemia, a challenging blood cancer. This collaboration between Blackstone Life Sciences and Johnson & Johnson could lead to significant advancements in the pharmaceutical and biotechnology sectors.
Blackstone Life Sciences and Johnson & Johnson have entered into a research and development funding agreement to advance the clinical development of bleximenib (JNJ-75276617), an investigational oral menin inhibitor for acute myeloid leukemia (AML). This marks the first co-funding agreement between the two entities. Bleximenib is currently in Phase 1, 2, and 3 clinical trials, being evaluated as both a monotherapy and in combination with other AML-directed therapies. The drug targets a key oncogenic interaction between menin and KMT2A proteins, which drives leukemic cell growth in patients with specific gene rearrangements or mutations. AML is an aggressive and fast-progressing blood cancer with high relapse rates and poor outcomes, highlighting the urgent need for more effective treatment options.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard